CERTIFICATIONS

Positive evaluation by EFSA
regarding the bioavailability and safety of IHAT™ (EFSA Scientific Opinion n. 27/10/2021)

Market authorization
as a novel food (Commission Implementing Regulation EU 2022/1373 del 5/8/2022)

Insertion into the Annex II list
as a novel food (Official Journal EU n. 2024/248 del 17/01/2024)

PUBLICATIONS

Latunde-Dada G. et al. A Nanoparticulate Ferritin-Core Mimetic Is Well Taken Up by HuTu 80 Duodenal Cells and Its Absorption in Mice Is Regulated by Body Iron. J Nutr. 2014 Dec;144(12):1896-902

Pereira D. et al. Caco-2 Cell Acquisition of Dietary Iron(III) Invokes a Nanoparticulate Endocytic Pathway. PLoS ONE 8(11): e81250.

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Safety of iron hydroxide adipate tartrate as a novel food pursuant to Regulation (EU) 2015/2283 and as a source of iron in the context of Directive 2002/46/EC. EFSA Journal 2021;19(12):6935

Pereira D. et al. Nanoparticulate iron(III) oxo-hydroxide delivers safe iron that is well absorbed and utilised in humans. Nanomedicine: Nanotechnology, Biology, and Medicine 10 (2014) 1877–1886

Powell J. et al. A nano-disperse ferritin-core mimetic that efficiently corrects anemia without luminal iron redox activity. Nanomedicine: Nanotechnology, Biology, and Medicine 10 (2014) 1529–1538

Lewis ED. et al. Safe and effective delivery of supplemental iron to healthy adults: a two-phase, randomized, double-blind trial – the safe iron study Front. Nutr. 2023 10:1230061

Mohammed N. et al. A novel nano-iron supplement versus standard treatment for iron deficiency anaemia in children 6–35 months (IHAT-GUT trial): a double-blind, randomised, placebo-controlled non-inferiority phase II trial in The Gambia. eClinicalMedicine, Volume 56, 101853